AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion for 120 minutes
Number of subjects: 85
Study 32247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 1.5 mU/kg/minute for 60 minutes
Number of subjects: 85
Study 32247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 0.5 mU/kg/minute for 60 minutes
Number of subjects: 85
Study 32247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 3.0 mU/kg/minute for 60 minutes
Number of subjects: 85
Study 32247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion at 1.5 mU/kg/minute for 60 minutes in metabolic syndrome and T2DM participants
Number of subjects: 85
Study 32247531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dextrose infusion for 120 minutes following revascularization for STEMI
Number of subjects: 85
Study 32247531 — intervention group
Group type: COMPARATOR
Intervention: Standard care following revascularization for STEMI
Number of subjects: 85
Study 34816585 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAR gene classifier
Number of subjects: 350
Study 33234812 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based group (n=20; 30 min of seated resting in a heated swimming pool at 30-32 °C)
Number of subjects: 35
Study 33234812 — intervention group
Group type: COMPARATOR
Intervention: Land-based group (n=15; 30 min of seated resting in a quiet room at 21-23 °C)
Number of subjects: 35
Study 36037565 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 50 mg blackberry powder (BG)
Number of subjects: 50
Study 36037565 — intervention group
Group type: COMPARATOR
Intervention: Chewing gum containing 700 mg xylitol (CG)
Number of subjects: 50
Study 33737296 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically inferred telomere length
Number of subjects: 20949
Study 36457207 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovator brand itraconazole 100 mg twice a day for 4 weeks
Number of subjects: 100
Study 36457207 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinational brand itraconazole 100 mg twice a day for 4 weeks
Number of subjects: 100
Study 36457207 — intervention group
Group type: EXPERIMENTAL
Intervention: Local generic brand itraconazole 100 mg twice a day for 4 weeks
Number of subjects: 100
Study 34900928 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective efficacy beliefs questionnaire
Number of subjects: 0
Study 34900928 — intervention group
Group type: COMPARATOR
Intervention: Absence of appreciation and support in the psychosocial environment
Number of subjects: 0
Study 34374086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (225 mg, three monthly doses)
Number of subjects: 838
Study 34374086 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 838
Study 34374086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study 32970574 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-sale naloxone availability
Number of subjects: 98
Study 32970574 — intervention group
Group type: COMPARATOR
Intervention: Chain pharmacies
Number of subjects: 98
Study 32970574 — intervention group
Group type: COMPARATOR
Intervention: Independent pharmacies
Number of subjects: 98
Study 32970574 — intervention group
Group type: COMPARATOR
Intervention: Rural areas
Number of subjects: 98
Study 32970574 — intervention group
Group type: COMPARATOR
Intervention: Statutory awareness
Number of subjects: 98
Study 35128781 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed rotational atherectomy (RA)
Number of subjects: 440
Study 33709937 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based unguided self-help and psychoeducation (AdultCan RCT)
Number of subjects: 2360
Study 33709937 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapist-supported cognitive behavioral therapy (Heart RCT)
Number of subjects: 2360
Study 33709937 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 2360
Study 33709937 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders for questionnaire completion
Number of subjects: 2360
Study 33709937 — intervention group
Group type: EXPERIMENTAL
Intervention: No reminder
Number of subjects: 2360
Study 35635180 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Number of subjects: 264
Study 35635180 — intervention group
Group type: COMPARATOR
Intervention: Control (standardized enhanced recovery strategies without breathing exercises)
Number of subjects: 264
Study 33764654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.25 mg/kg/dose)
Number of subjects: 287
Study 33764654 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone (0.5 mg/kg/dose)
Number of subjects: 287
Study 32201441 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 60
Study 32201441 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 60
Study 35696440 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including physician training in risk-based treatment, subsidized losartan-HCTZ single-pill combination medications, nurse training in motivational conversations, and telephone follow-ups.
Number of subjects: 916
Study 35696440 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 916
Study 35696440 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 916
Study 34187701 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation
Number of subjects: 130687
Study 34187701 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted consumption of alcohol
Number of subjects: 130687
Study 34187701 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted consumption of coffee
Number of subjects: 130687
Study 32733948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on independent prognostic factors (age, marital status, grade, tumor size, AJCC 8th edition T stage and M stage, LODDS)
Number of subjects: 0
Study 32733948 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curve and ROC curve validation
Number of subjects: 0
Study 36418566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 175
Study 36418566 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 175
Study 35129523 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (surgery within 6 weeks)
Number of subjects: 88
Study 35129523 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-first approach
Number of subjects: 88
Study 33009489 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone (AAP) - abiraterone 1000 mg/day plus prednisone 10 mg/day
Number of subjects: 51
Study 33009489 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide - 160 mg/day
Number of subjects: 51
Study 36342811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lianhua Qingwen capsule (LH), 4 capsules, thrice daily for 14 days
Number of subjects: 120
Study 32466729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease events
Number of subjects: 15076
Study 32466729 — intervention group
Group type: EXPERIMENTAL
Intervention: Computable phenotype implementation
Number of subjects: 15076
Study 32466729 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment methods
Number of subjects: 15076
Study 32646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (Texas Medication Algorithm Project)
Number of subjects: 139
Study 32646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher load of life events and difficulties (LEDs) related to entrapment and humiliation
Number of subjects: 139
Study 32646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of external entrapment (Entrapment Scale)
Number of subjects: 139
Study 32646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical data, severity of depression, social ranking, evolution informed variables, LEDs, childhood maltreatment
Number of subjects: 139
Study 32646266 — intervention group
Group type: EXPERIMENTAL
Intervention: External entrapment
Number of subjects: 139
Study 32804892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with FMR and TFL
Number of subjects: 25
Study 32804892 — intervention group
Group type: COMPARATOR
Intervention: FMR alone
Number of subjects: 25
Study 32907282 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB (CHO)
Number of subjects: 322
Study 32907282 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB (SC)
Number of subjects: 322
Study 32907282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-booster anti-HBs between 2.5 mIU/ml and 10 mIU/ml
Number of subjects: 322
Study 32907282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 322
Study 32907282 — intervention group
Group type: COMPARATOR
Intervention: Anti-HBs <2.5 mIU/ml
Number of subjects: 322
Study 32907282 — intervention group
Group type: COMPARATOR
Intervention: Anti-HBs 2.5-10 mIU/ml
Number of subjects: 322
Study 34187068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured-portal group
Number of subjects: 91
Study 34187068 — intervention group
Group type: COMPARATOR
Intervention: Open-portal group
Number of subjects: 91
Study 34187068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 34886221 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal–Visual feedback (VER&VIS)
Number of subjects: 61
Study 34886221 — intervention group
Group type: COMPARATOR
Intervention: Verbal feedback (VER)
Number of subjects: 61
Study 34886221 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback (VIS)
Number of subjects: 61
Study 33836974 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (150 mg on days 5 to 18) and T-DM1 (day 1 intravenous) in 21-day treatment cycles
Number of subjects: 18
Study 33836974 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib and T-DM1
Number of subjects: 18
Study 32384914 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 542
Study 32384914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with rescue with ketamine)
Number of subjects: 542
Study 35609204 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 21
Study 34000088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7487
Study 34000088 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual-antiplatelet therapy (DAPT)
Number of subjects: 7487
Study 34000088 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE risk score 2.0
Number of subjects: 7487
Study 36093646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV) with tidal volume adjusted to a target plateau pressure (Pplat ≤ 20 cm H2O) and PEEP (9 cm H2O)
Number of subjects: 61
Study 36093646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV)
Number of subjects: 61
Study 36093646 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV) (8 ml/kg‐1VT)
Number of subjects: 61
Study 36093646 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 61
Study 32927478 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol/kg/min)
Number of subjects: 6
Study 32927478 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of Exendin 9-39 (Ex 9-39) (900 pmol/kg/min) with GLP-1
Number of subjects: 6
Study 32927478 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 infusion alone
Number of subjects: 6
Study 32927478 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of Ex 9-39
Number of subjects: 6
Study 32927478 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion and Ex 9-39
Number of subjects: 6
Study 32452928 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted muscle reinnervation
Number of subjects: 33
Study 33357070 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (50 mg·kg‐1)
Number of subjects: 11
Study 33357070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 33357070 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 11
Study 33610734 — intervention group
Group type: EXPERIMENTAL
Intervention: zolbetuximab + EOX (800 mg/m2 loading dose, then 600 mg/m2 Q3W)
Number of subjects: 246
Study 33610734 — intervention group
Group type: EXPERIMENTAL
Intervention: zolbetuximab + EOX (1000 mg/m2 Q3W)
Number of subjects: 246
Study 33610734 — intervention group
Group type: COMPARATOR
Intervention: EOX alone
Number of subjects: 246
Study 33884942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Computed Tomography (CCT)
Number of subjects: 0
Study 33884942 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT
Number of subjects: 0
Study 32503507 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussing LUTS with personal relations
Number of subjects: 4885
Study 32503507 — intervention group
Group type: EXPERIMENTAL
Intervention: Having an available social network
Number of subjects: 4885
Study 32503507 — intervention group
Group type: COMPARATOR
Intervention: Not discussing symptoms with personal or professional relations
Number of subjects: 4885
Study 631083998 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-paretic arm training (40 minutes/day, three days/week for four weeks)
Number of subjects: 19
Study 631083998 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-paretic arm training
Number of subjects: 19
Study 631083998 — intervention group
Group type: COMPARATOR
Intervention: Regular therapy (during the four-week control period)
Number of subjects: 19
Study 36333727 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach McLungsSM intervention
Number of subjects: 21
Study 36333727 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 21
Study 32658018 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral spike distance ratio
Number of subjects: 22
Study 32658018 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral spike distance >2 times the femoral radius
Number of subjects: 22
Study 32658018 — intervention group
Group type: COMPARATOR
Intervention: Femoral spike area ratio
Number of subjects: 22
Study 32120445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion administered immediately after incision of the visceral peritoneum (Group I)
Number of subjects: 101
Study 32120445 — intervention group
Group type: COMPARATOR
Intervention: Control group (Oxytocin infusion administered immediately after clamping the umbilical cord, Group II)
Number of subjects: 101
Study 32120445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (Group I)
Number of subjects: 101
Study 32120445 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 101
Study 35911242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 30
Study 35911242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32122153 — intervention group
Group type: EXPERIMENTAL
Intervention: PleuraFlow® 32 F chest tube with FlowGlide™ active clearance
Number of subjects: 100
Study 32122153 — intervention group
Group type: COMPARATOR
Intervention: Argyle® 32 F chest tube
Number of subjects: 100
Study 34496448 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg esketamine (SK0)
Number of subjects: 90
Study 34496448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg esketamine (SK0.25)
Number of subjects: 90
Study 34496448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg esketamine (SK0.5)
Number of subjects: 90
Study 33556518 — intervention group
Group type: EXPERIMENTAL
Intervention: NPO
Number of subjects: 90
Study 33556518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear liquids
Number of subjects: 90
Study 33556518 — intervention group
Group type: COMPARATOR
Intervention: Control (regular diet)
Number of subjects: 90
Study 32408905 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-free chemotherapy regimen (6x docetaxel/cyclophosphamide, TC)
Number of subjects: 0
Study 32408905 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-taxane sequence (4xEC followed by 4x docetaxel)
Number of subjects: 0
Study 32408905 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 0
Study 32408905 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by endocrine therapy
Number of subjects: 0
Study 35631240 — intervention group
Group type: EXPERIMENTAL
Intervention: Eufortyn® Colesterolo Plus
Number of subjects: 60
Study 35631240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34444645 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein‐rich nutritional composition supplementation (PS)
Number of subjects: 100
Study 34776172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 12
Study 34776172 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Exercise A (SEA)
Number of subjects: 12
Study 34776172 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Exercise B (SEB)
Number of subjects: 12
Study 34776172 — intervention group
Group type: COMPARATOR
Intervention: Control (PRE)
Number of subjects: 12
Study 34776172 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Exercises (SEA and SEB)
Number of subjects: 12
Study 32339775 — intervention group
Group type: EXPERIMENTAL
Intervention: FS4 coding strategy
Number of subjects: 34
Study 32339775 — intervention group
Group type: COMPARATOR
Intervention: FSP coding strategy
Number of subjects: 34
Study 32339775 — intervention group
Group type: EXPERIMENTAL
Intervention: FS4 and FSP coding strategies
Number of subjects: 34
Study 35692883 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol combined with zoledronic acid
Number of subjects: 60
Study 35692883 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 60
Study 33771846 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice (self-collection at home for HPV testing)
Number of subjects: 0
Study 33771846 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care screening (cytology and HPV co-testing at Health Department clinics)
Number of subjects: 0
Study 36069743 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychoeducational support group (6 sessions, 35-45 minutes each, via WhatsApp)
Number of subjects: 70
Study 36069743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 33063950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's vocalizations and gaze to partner's face and objects
Number of subjects: 0
Study 33063950 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants' vocalizations timed with gaze to partner's face
Number of subjects: 0
Study 33063950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic coordination of vocalizations and gaze
Number of subjects: 0
Study 35400202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP 110-139 mm Hg)
Number of subjects: 1000
Study 35400202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-to-low SBP group (from >210 mm Hg to <140 mm Hg)
Number of subjects: 1000
Study 35400202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-to-low SBP group
Number of subjects: 1000
Study 35400202 — intervention group
Group type: COMPARATOR
Intervention: Moderate SBP group
Number of subjects: 1000
Study 35400202 — intervention group
Group type: COMPARATOR
Intervention: High SBP group
Number of subjects: 1000
Study 34637343 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (all doses combined)
Number of subjects: 354
Study 34637343 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (45 mg)
Number of subjects: 354
Study 34637343 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (70 mg)
Number of subjects: 354
Study 34637343 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (C3SR Inattention)
Number of subjects: 354
Study 34637343 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (CGI-I responders)
Number of subjects: 354
Study 34637343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 34637343 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (open-label treatment)
Number of subjects: 354
Study 32149858 — intervention group
Group type: EXPERIMENTAL
Intervention: Full multiparametric CAD
Number of subjects: 4783
Study 32149858 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated-protocol CAD
Number of subjects: 4783
Study 32149858 — intervention group
Group type: COMPARATOR
Intervention: BI-RADS 3 and 4 lesions
Number of subjects: 4783
Study 36333773 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin
Number of subjects: 88
Study 36333773 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) plus metformin
Number of subjects: 88
Study 34024185 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) scarf osteotomy
Number of subjects: 58
Study 34024185 — intervention group
Group type: COMPARATOR
Intervention: Open scarf osteotomy
Number of subjects: 58
Study 32299380 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 41
Study 32299380 — intervention group
Group type: COMPARATOR
Intervention: High-definition white-light endoscopy (HD-WLE)
Number of subjects: 41
Study 35192050 — intervention group
Group type: EXPERIMENTAL
Intervention: RückenSPEZIAL (interdisciplinary second opinion procedure)
Number of subjects: 216
Study 35192050 — intervention group
Group type: EXPERIMENTAL
Intervention: RückenSPEZIAL with ISOP and IMPT
Number of subjects: 216
Study 35192050 — intervention group
Group type: EXPERIMENTAL
Intervention: RückenSPEZIAL with solely ISOP without IMPT
Number of subjects: 216
Study 35192050 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 216
Study 33421630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (patients with atrial fibrillation)
Number of subjects: 398
Study 33421630 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without atrial fibrillation)
Number of subjects: 398